OrbiMed’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

OrbiMed’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-7,520,600	Closed	-$22.2M	–	186
2021 Q3	$22.2M	Hold	7,520,600	–	–	0.24%	93
2021 Q2	$18.8M	Hold	7,520,600	–	–	0.19%	102
2021 Q1	$21.9M	Sell	7,520,600 -2,000,000	-21%	-$6.53M	0.2%	96
2020 Q4	$30.7M	Hold	9,520,600	–	–	0.27%	82
2020 Q3	$20.5M	Hold	9,520,600	–	–	0.26%	84
2020 Q2	$11M	Hold	9,520,600	–	–	0.16%	96
2020 Q1	$8.76M	Buy	9,520,600 +4,520,600	+90%	+$5.18M	0.15%	90
2019 Q4	$7.9M	Hold	5,000,000	–	–	0.11%	88
2019 Q3	$4.18M	Hold	5,000,000	–	–	0.08%	98
2019 Q2	$4.3M	Hold	5,000,000	–	–	0.07%	114
2019 Q1	$4.85M	Hold	5,000,000	–	–	0.08%	109
2018 Q4	$3.67M	Hold	5,000,000	–	–	0.07%	109
2018 Q3	$10.8M	Hold	5,000,000	–	–	0.13%	110
2018 Q2	$24.9M	Hold	5,000,000	–	–	0.3%	76
2018 Q1	$19.5M	Hold	5,000,000	–	–	0.24%	82
2017 Q4	$13.4M	Hold	5,000,000	–	–	0.17%	93
2017 Q3	$15.9M	Hold	5,000,000	–	–	0.15%	91
2017 Q2	$16.6M	Buy	+5,000,000	New	+$19.5M	0.17%	85

Other funds holding CTIC

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return

ACM

Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

LPC

Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

OrbiMed's CTIC Position: Q4 2021 in Review

OrbiMed sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q4 2021, closing a stake of 7,520,600 shares — an estimated $22.2M sold.

OrbiMed first reported a position in CTIC in Q2 2017 and held it in 18 quarters. The position peaked at $30.7M in Q4 2020. 63 funds tracked by Wall St. Rank hold CTIC as of Q4 2021.

OrbiMed reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q4 2021 after selling out during the quarter.
OrbiMed sold 7,520,600 CTI BioPharma Corp. (DE) Common Stock shares in Q4 2021, an estimated $22.2M.
OrbiMed first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2017 and held it in 18 quarters.
OrbiMed's CTI BioPharma Corp. (DE) Common Stock position peaked at $30.7M in Q4 2020.
63 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q4 2021.

Based on OrbiMed's 13F filing for Q4 2021, filed 14 Feb 2022.